Home Biosimilar Antibodies Others Others Prasinezumab (Anti-Alpha-synuclein)
For research use only. Not for use in humans.

Prasinezumab (Anti-Alpha-synuclein)

Synonyms: PRX 002

Prasinezumab (Anti-Alpha-synuclein) is a humanized IgG1 monoclonal antibody targeting aggregated α-synuclein.It has the potential for Parkinson's disease research. MW :150 KD.

Prasinezumab (Anti-Alpha-synuclein)

Quality Control

Batch: A262301 Purity: 99% Protein concentration: 6.016mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Prasinezumab (Anti-Alpha-synuclein) is a humanized IgG1 monoclonal antibody targeting aggregated α-synuclein.It has the potential for Parkinson's disease research. MW :150 KD.
References

Product Details

CAS No. 1960462-19-4
Molecular Weight 150
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07055087 NOT_YET_RECRUITING Drug: Prasinezumab|Drug: Sodium Chloride Parkinson's Disease University Hospital Tuebingen 2025-12 PHASE2
NCT07174310 RECRUITING Drug: Prasinezumab|Drug: Placebo Parkinson's Disease Hoffmann-La Roche 2025-11-24 PHASE3
NCT04777331 ACTIVE_NOT_RECRUITING Drug: Prasinezumab|Drug: Placebo Parkinsons Disease Hoffmann-La Roche 2021-05-05 PHASE2
NCT03100149 ACTIVE_NOT_RECRUITING Drug: RO7046015|Drug: RO7046015|Drug: Placebo Parkinson's Disease Hoffmann-La Roche 2017-06-27 PHASE2

(data from https://clinicaltrials.gov, updated on 2025-07-08)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.